Cargando…

Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?

SIMPLE SUMMARY: Over the last decade, the treatment of patients diagnosed with melanoma has transformed with the introduction of checkpoint inhibitors and targeted therapies. However, innate or acquired resistance, as well as toxicities of these treatments demands additional options for patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakish, Hanna H., Ahmed, Fasih Ali, Elshami, Mohamedraed, Loftus, Alexander W., Hoehn, Richard S., Ammori, John B., Ocuin, Lee M., Winter, Jordan M., Bordeaux, Jeremy S., Mangla, Ankit, Rothermel, Luke D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658976/
https://www.ncbi.nlm.nih.gov/pubmed/36358601
http://dx.doi.org/10.3390/cancers14215184
_version_ 1784830087131037696
author Kakish, Hanna H.
Ahmed, Fasih Ali
Elshami, Mohamedraed
Loftus, Alexander W.
Hoehn, Richard S.
Ammori, John B.
Ocuin, Lee M.
Winter, Jordan M.
Bordeaux, Jeremy S.
Mangla, Ankit
Rothermel, Luke D.
author_facet Kakish, Hanna H.
Ahmed, Fasih Ali
Elshami, Mohamedraed
Loftus, Alexander W.
Hoehn, Richard S.
Ammori, John B.
Ocuin, Lee M.
Winter, Jordan M.
Bordeaux, Jeremy S.
Mangla, Ankit
Rothermel, Luke D.
author_sort Kakish, Hanna H.
collection PubMed
description SIMPLE SUMMARY: Over the last decade, the treatment of patients diagnosed with melanoma has transformed with the introduction of checkpoint inhibitors and targeted therapies. However, innate or acquired resistance, as well as toxicities of these treatments demands additional options for patients with advanced melanoma. We reviewed the landscape of phase 3 clinical trials to identify trends in clinical trial investment, as well as emerging treatments with exploratory mechanisms (mechanisms not previously approved by the FDA for melanoma) that may change the way melanoma is treated in the future. ABSTRACT: Background: Several drugs and treatment modalities are under investigation to improve current melanoma therapy options. This review profiles the trends in clinical trial investment in late-stage melanoma, and anticipates what changes are expected in melanoma treatment, with a focus on exploratory drug mechanisms. Methods: We reviewed nine international clinical trial databases for registered, interventional, and phase 3 cutaneous melanoma clinical trials since 2010. Results: 73 trials studied drug therapies in late-stage (stage III and IV) melanoma. Exploratory mechanisms were investigated in 32% (23/73) of the late-stage melanoma drug therapy trials. Most exploratory drug trials include immunotherapy drug mechanisms (15/23 trials). Two exploratory mechanisms showed promise: the anti-LAG3 antibody, relatlimab, and the hapten modified vaccine, MVax. Many (52%) trials of exploratory mechanisms are ongoing including the use of adoptive cell transfer immunotherapies, dendritic cell vaccine therapy, and histone deacetylase (HDAC) inhibitors, among others. Conclusions: Since most clinical trials focus on previously approved drug mechanisms, it is likely that paradigm-changing treatments will involve these therapies being used in new treatment contexts or combinations. Only 2 exploratory drug mechanisms studied since 2010 have achieved promising results in the phase 3 setting, though many other trials are ongoing at this time.
format Online
Article
Text
id pubmed-9658976
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96589762022-11-15 Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms? Kakish, Hanna H. Ahmed, Fasih Ali Elshami, Mohamedraed Loftus, Alexander W. Hoehn, Richard S. Ammori, John B. Ocuin, Lee M. Winter, Jordan M. Bordeaux, Jeremy S. Mangla, Ankit Rothermel, Luke D. Cancers (Basel) Review SIMPLE SUMMARY: Over the last decade, the treatment of patients diagnosed with melanoma has transformed with the introduction of checkpoint inhibitors and targeted therapies. However, innate or acquired resistance, as well as toxicities of these treatments demands additional options for patients with advanced melanoma. We reviewed the landscape of phase 3 clinical trials to identify trends in clinical trial investment, as well as emerging treatments with exploratory mechanisms (mechanisms not previously approved by the FDA for melanoma) that may change the way melanoma is treated in the future. ABSTRACT: Background: Several drugs and treatment modalities are under investigation to improve current melanoma therapy options. This review profiles the trends in clinical trial investment in late-stage melanoma, and anticipates what changes are expected in melanoma treatment, with a focus on exploratory drug mechanisms. Methods: We reviewed nine international clinical trial databases for registered, interventional, and phase 3 cutaneous melanoma clinical trials since 2010. Results: 73 trials studied drug therapies in late-stage (stage III and IV) melanoma. Exploratory mechanisms were investigated in 32% (23/73) of the late-stage melanoma drug therapy trials. Most exploratory drug trials include immunotherapy drug mechanisms (15/23 trials). Two exploratory mechanisms showed promise: the anti-LAG3 antibody, relatlimab, and the hapten modified vaccine, MVax. Many (52%) trials of exploratory mechanisms are ongoing including the use of adoptive cell transfer immunotherapies, dendritic cell vaccine therapy, and histone deacetylase (HDAC) inhibitors, among others. Conclusions: Since most clinical trials focus on previously approved drug mechanisms, it is likely that paradigm-changing treatments will involve these therapies being used in new treatment contexts or combinations. Only 2 exploratory drug mechanisms studied since 2010 have achieved promising results in the phase 3 setting, though many other trials are ongoing at this time. MDPI 2022-10-22 /pmc/articles/PMC9658976/ /pubmed/36358601 http://dx.doi.org/10.3390/cancers14215184 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kakish, Hanna H.
Ahmed, Fasih Ali
Elshami, Mohamedraed
Loftus, Alexander W.
Hoehn, Richard S.
Ammori, John B.
Ocuin, Lee M.
Winter, Jordan M.
Bordeaux, Jeremy S.
Mangla, Ankit
Rothermel, Luke D.
Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?
title Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?
title_full Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?
title_fullStr Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?
title_full_unstemmed Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?
title_short Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?
title_sort trends in melanoma phase 3 clinical trials since 2010: is there hope for advanced melanoma therapies beyond approved treatment mechanisms?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658976/
https://www.ncbi.nlm.nih.gov/pubmed/36358601
http://dx.doi.org/10.3390/cancers14215184
work_keys_str_mv AT kakishhannah trendsinmelanomaphase3clinicaltrialssince2010istherehopeforadvancedmelanomatherapiesbeyondapprovedtreatmentmechanisms
AT ahmedfasihali trendsinmelanomaphase3clinicaltrialssince2010istherehopeforadvancedmelanomatherapiesbeyondapprovedtreatmentmechanisms
AT elshamimohamedraed trendsinmelanomaphase3clinicaltrialssince2010istherehopeforadvancedmelanomatherapiesbeyondapprovedtreatmentmechanisms
AT loftusalexanderw trendsinmelanomaphase3clinicaltrialssince2010istherehopeforadvancedmelanomatherapiesbeyondapprovedtreatmentmechanisms
AT hoehnrichards trendsinmelanomaphase3clinicaltrialssince2010istherehopeforadvancedmelanomatherapiesbeyondapprovedtreatmentmechanisms
AT ammorijohnb trendsinmelanomaphase3clinicaltrialssince2010istherehopeforadvancedmelanomatherapiesbeyondapprovedtreatmentmechanisms
AT ocuinleem trendsinmelanomaphase3clinicaltrialssince2010istherehopeforadvancedmelanomatherapiesbeyondapprovedtreatmentmechanisms
AT winterjordanm trendsinmelanomaphase3clinicaltrialssince2010istherehopeforadvancedmelanomatherapiesbeyondapprovedtreatmentmechanisms
AT bordeauxjeremys trendsinmelanomaphase3clinicaltrialssince2010istherehopeforadvancedmelanomatherapiesbeyondapprovedtreatmentmechanisms
AT manglaankit trendsinmelanomaphase3clinicaltrialssince2010istherehopeforadvancedmelanomatherapiesbeyondapprovedtreatmentmechanisms
AT rothermelluked trendsinmelanomaphase3clinicaltrialssince2010istherehopeforadvancedmelanomatherapiesbeyondapprovedtreatmentmechanisms